Table 4.
Treatment-related factors associated with OS limited in patients with IPF.
| Characteristics | n | OS | |||
|---|---|---|---|---|---|
| Median OS (days) | Univariate analysis | Multivariate analysis | |||
| p value | HR (95% CI) | p value | |||
| Chemoradiotherapy in LD stage | |||||
| Chemoradiotherapy | 16 | 355 | 0.0012 | 5.02 (1.84−13.68) | 0.0016 |
| Chemotherapy | 10 | 1163 | |||
| Platinum agents | |||||
| Carboplatin | 63 | 318 | 0.0301 | 1.51 (0.70−3.24) | 0.2923 |
| Cisplatin | 12 | 626 | |||
| Another chemotherapeutic agent | |||||
| Irinotecan | 8 | 621 | 0.7525 | ||
| Etoposide | 67 | 355 | |||
| Number of cycles of first-line chemotherapy | |||||
| 1–3 | 29 | 167 | 0.0008 | 2.02 (1.17−3.49) | 0.0120 |
| 4–6 | 46 | 469 | |||
| Acute exacerbation of IPF | |||||
| Yes | 9 | 262 | 0.3942 | ||
| No | 65 | 361 | |||
| Response to first-line therapy | |||||
| SD/PD | 22 | 167 | < 0.0001 | 2.64 (1.46−4.77) | 0.0013 |
| CR/PR | 52 | 471 | |||
CI, confidence interval; CR, complete response; HR, hazard ratio; IPF, idiopathic pulmonary fibrosis; LD, limited disease; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease.